Skip to main navigation Skip to search Skip to main content

A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCI in Acutely Psychotic Patients with Schizophrenia

Project: Research

Project Details

StatusFinished
Effective start/end date03/1/08 → 02/28/14

Funding

  • Sumitomo Pharma America Incorporated: $280,705.62